GSK840
|
|
|
- CAS号:
- 2361146-30-5
- 英文名:
- GSK840
- 英文别名:
- GSK840;tert-butyl2-(4-(5-(methylcarbamoyl)-1H-benzo[d]im;tert-butyl 2-(4-(5-(methylcarbamoyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetate;Inhibitor,RIP kinase,GSK 840,Receptor-interacting protein kinases,GSK840,inhibit,GSK-840,RIPK;Benzeneacetic acid, 4-[5-[(methylamino)carbonyl]-1H-benzimidazol-1-yl]-, 1,1-dimethylethyl ester
- 中文名:
- GSK840
- 中文别名:
- 化合物GSK840;化合物 T11501
- CBNumber:
- CB95419747
- 分子式:
- C21H23N3O3
- 分子量:
- 365.43
- MOL File:
- 2361146-30-5.mol
|
|
|
GSK840化学性质
-
密度:
-
1.18±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
110 mg/mL in DMSO
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
14.16±0.46(Predicted)
-
|
-
颜色:
-
Light yellow to yellow
-
|
GSK840性质、用途与生产工艺
GSK840 (GSK'840) 是一种受体相互作用蛋白激酶 3 (RIP3 或 RIPK3) 抑制剂，高亲和力结合 RIP3 激酶结构域，IC50 值为 0.9 nM，并抑制激酶活性，IC50 值为 0.3 nM。
GSK840 (GSK'840) (0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in a concentration-dependent manner.
GSK840 binds the kinase domain and inhibits kinase activity with high specificity, targeting a broader range of pro-necrotic stimuli than can be achieved with RIP1 kinase inhibitors.
Cell Viability Assay
|
Cell Line:
|
Human HT-29 cells (TNF 10 ng/ml + zVAD-fmk 20 μM + SMAC007 100 nM)
|
|
Concentration:
|
0.01-3 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
Blocked TNF-induced necroptosis in a concentration-dependent manner.
|
GSK840
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/08/19 | HY-104021 | GSK840
GSK840 | 2361146-30-5 | 5mg | 720元 |
| 2024/08/19 | HY-104021 | GSK840
GSK840 | 2361146-30-5 | 10mM * 1mLin DMSO | 792元 |
2361146-30-5, GSK840 相关搜索:
- 抑制剂
- 化合物GSK840
- 化合物 T11501
- 2361146-30-5
- Benzeneacetic acid, 4-[5-[(methylamino)carbonyl]-1H-benzimidazol-1-yl]-, 1,1-dimethylethyl ester
- tert-butyl2-(4-(5-(methylcarbamoyl)-1H-benzo[d]im
- Inhibitor,RIP kinase,GSK 840,Receptor-interacting protein kinases,GSK840,inhibit,GSK-840,RIPK
- tert-butyl 2-(4-(5-(methylcarbamoyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetate
- GSK840